Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon
Medtronic Symplicity Spyral renal denervation

FDA approves another renal denervation system for hypertension

This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

Thumbnail

University of Wisconsin and GE HealthCare expand 40-year partnership

Their goal is to shape the future of medical imaging, enhance the standard of care, and improve patient outcomes by incorporating advancements in AI and digital solutions. 

Thumbnail

Gene-editing therapy lowers cholesterol in high-risk heart patients—one dose could potentially last decades

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

Prosthesis-patient mismatch (PPM) after TAVR

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

Thumbnail

Downstream costs of noninvasive cardiac diagnostics revealed in data study

At what looks to be an 18% cost savings downstream, stress echocardiograms looks to be the least expensive diagnostic procedure for patients with chest pain

cannabis use disorder marijuana joint weed smoking

Daily marijuana use increases heart failure risk by 34%

“Marijuana use isn’t without its health concerns, and our study provides more data linking its use to cardiovascular conditions," one researcher said. 

CVD deaths have increased dramatically, undoing years of progress

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

Thumbnail

TAVR linked to favorable outcomes for asymptomatic and minimally symptomatic patients—but is it necessary?

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

Displaying 1009 - 1016 of 5936
Design by Adaptive Theme